The company admitted that it marketed Depakote for unapproved uses, including treatment of schizophrenia, agitated dementia and autism. The case includes a criminal fine and forfeiture of $700 million and civil settlements with the federal government and states totaling $800 million.
» E-Mail This    » Add to Del.icio.us
from News